Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for oncology and obesity. The company advances a pipeline of targeted treatments, including CRB-701, a next-generation antibody drug conjugate that targets Nectin-4 expression on cancer cells to deliver a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody designed to block TGFβ activation on cancer cells; and CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist aimed at obesity treatment. These candidates focus on well-understood biological pathways to address serious unmet medical needs in cancer care and weight management. Corbus Pharmaceuticals Holdings, Inc. conducts rigorous clinical trials to evaluate safety, tolerability, and efficacy, with programs in advanced stages for solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and bladder cancer, as well as obesity studies showing promising early weight loss data. Headquartered in Norwood, Massachusetts, the company operates in the high-stakes biopharma sector, emphasizing precision medicine to improve patient outcomes in critical therapeutic areas.